Introduction
The mitogen-activated protein (MAP) kinase signaling pathways are important mediators of cellular responses to extracellular signals that include growth factors, hormones, cytokines and environmental stresses (Chang and Karin, 2001) . These pathways are evolutionarily conserved among eukaryotes and feature a triple kinase cascade comprised of the MAP kinase which is phosphorylated and activated by a MAP kinase kinase (MKK), which itself is phosphorylated and activated by a MAP kinase kinase kinase (MKKK) (Chang and Karin, 2001) . In mammals, four distinct MAP kinase pathways have been identified that lead to the activation of the extracellular signal-regulated kinase (ERK), ERK5, c-Jun N-terminal kinase (JNK) and p38 (Chang and Karin, 2001) .
The JNK and p38 MAP kinases are collectively referred to as stress-activated MAP kinases. They are activated in response to a variety of environmental stresses and pro-inflammatory cytokines, and also play important roles in development (Davis, 2000; Kyriakis and Avruch, 2001) . A number of MKKs can phosphorylate and activate JNK and p38. MKK3 and MKK6 activate p38, MKK7 activates JNK, whereas MKK4 can activate both JNK and p38 (Davis, 2000; Kyriakis and Avruch, 2001) (Figure 1a ). The JNK and p38 pathways are implicated in tumor suppression Bulavin and Fornace Jr, 2004) and this is supported by the presence of loss of function mutations in the MKK4 gene in approximately 5% of human tumors from a variety of tissues (Teng et al., 1997; Su et al., 1998) . However, it is also reported that MKK4 and JNK can participate in tumor formation suggesting a more complex role for this pathway in tumor development Wang et al., 2004) .
In this review, we describe the properties of MKK4 and examine how this protein kinase and its downstream targets contribute to controlling the development of cancers.
Biochemical properties of MKK4
Cloning, structure and tissue distribution of MKK4 MKK4 was first identified in screens for novel MKK family members in Xenopus laevis and termed XMEK2 (Yashar et al., 1993) . Subsequently the Drosophila, mouse and human homologs were cloned and named DMKK4, stress-activate protein kinase/extracellularsignal-regulated protein kinase kinase-1 and MKK4, respectively (Sanchez et al., 1994; De´rijard et al., 1995; Lin et al., 1995; Han et al., 1998) . The human MKK4 gene is located on chromosome 17 and encodes a protein of 399 amino acids (De´rijard et al., 1995; Yoshida et al., 1999) . Overall the mammalian MKK family share about 40% homology within their catalytic domains and MKK4 is most similar to MKK7 in this region (50% identity; Tournier et al., 1997; Cuenda, 2000) . The catalytic domains of MKKs, like other Ser/Thr kinases, contain 11 subdomains (Hanks et al., 1988) . The crystal structures of MEK1 and MEK2, the MKKs in the ERK pathway, demonstrate that MKKs fold into a small bstranded N-terminal lobe and a larger helical C-terminal lobe (Ohren et al., 2004) . The adenosine triphosphate binding site is located in the cleft formed between the two lobes and is surrounded by residues that are conserved between the MKK family members (Cuenda, 2000; Ohren et al., 2004) .
MKK4, similar to the other MKKs, also contains docking sites for both upstream and downstream components of the JNK and p38 signaling cascades (Xia et al., 1998; Ho et al., 2003; Takekawa et al., 2005; Figure 1b) . At the N-terminus there is a D-domain type docking site that binds to JNK and p38 (Ho et al., 2003) . In addition to MKKs, D-domain docking sites that bind to MAP kinases are found in many proteins involved in MAP kinase signaling including MAP kinase phosphatases, substrates, and scaffold or adaptor proteins (Sharrocks et al., 2000) . The region encompassing the D-domain may also participate in the binding of MKKKs to MKKs, although the major binding determinant is the domain for versatile docking (DVD) located in the C-terminus of MKKs (Xia et al., 1998; Takekawa et al., 2005; Figure 1b ). The interactions between MKKs and the upstream and downstream kinases of the cascade appear to be critical for efficient signal transfer through MAP kinase pathways (Xia et al., 1998; Ho et al., 2003; Takekawa et al., 2005) .
MKK4 mRNA is ubiquitously expressed in adult mouse and human tissue with the highest levels of expression in brain, in particular in the cerebral cortex, hypothalamus, hippocampus and cerebellum (Sanchez et al., 1994; De´rijard et al., 1995; Carboni et al., 1997; Lee et al., 1999) . In early embryogenesis in mice (up to embryonic day 10 (E10)), Mkk4 transcripts are confined to the central nervous system. Later, starting at E12, Mkk4 becomes highly expressed in the developing liver coincident with a period of active differentiation and an increase in liver size (Lee et al., 1999) . Subcellular localization studies demonstrate that MKK4 protein is mainly found in the cytoplasm, although some nuclear localization has been detected (Tournier et al., 1999; Coffey et al., 2000) .
MKK4 activation of JNK and p38 MAP kinases MKK4 is unique among the mammalian MKK family in its ability to phosphorylate and activate two MAP kinase groups: JNK and p38 (De´rijard et al., 1995; Lin et al., 1995) . MKK3 and MKK6 are specific for p38, whereas MKK7 is a specific JNK activator (Davis, 2000; Kyriakis and Avruch, 2001) . MKK4 activates all the mammalian JNK isoforms (JNK1, JNK2 and JNK3) and a subset of p38 isoforms (p38a, p38b) (De´rijard et al., 1995; Lin et al., 1995; Jiang et al., 1996) .
All MAP kinases are activated by phosphorylation of the Thr and Tyr residues of a Thr-X-Tyr motif located within kinase subdomain VIII (Chang and Karin, 2001) . Both residues need to be phosphorylated for full activation of the MAP kinase (Chang and Karin, 2001 ). However, it was observed in vitro that MKK4 preferentially phosphorylated the Tyr residue on JNK (Sanchez et al., 1994; Lin et al., 1995) , whereas the second JNK activator, MKK7, preferentially targeted the Thr residue (Lawler et al., 1998) . These observations led to the hypothesis that JNK isoforms are activated synergistically by MKK4 and MKK7 (Lawler et al., 1998; Fleming et al., 2000; Lisnock et al., 2000) . Some in vivo evidence to support this model has come from studies using mouse embryonic stem (ES) cells and mouse embryonic fibroblasts (MEFs) that feature targeted deletions of the Mkk4 and Mkk7 genes (Tournier et al., 2001; Wada et al., 2001; Kishimoto et al., 2003) . These studies also demonstrated that distinct stimuli might differentially utilize MKK4 and MKK7. For example, the activation of JNK in response to the pro-inflammatory cytokines tumor necrosis factor-a (TNFa) and interleukin-1 (IL-1) was almost completely abolished in Mkk7À/À MEFs, but reduced to around 50% activation in Mkk4À/À cells (Tournier et al., 2001) . This indicates that MKK7 is essential for JNK activation by these cytokines, whereas MKK4 contributes to optimal JNK activation. This is supported by studies demonstrating that TNFa and IL-1 preferentially activate MKK7 in vitro and in cells (Finch et al., 1997; Lawler et al., 1997; Moriguchi et al., 1997; Tournier et al., 2001) . In contrast, it was observed in Mkk4À/À and Mkk7À/À ES cells and MEFs that both MKK4 and MKK7 make similar contributions to JNK activation in response to a number of environmental stresses including UV radiation, heat shock and osmotic shock (Tournier et al., 2001; Kishimoto et al., 2003) . Although the studies described above provided strong genetic evidence to support the role of MKK4 as a JNK activator in vivo, it had been less clear whether MKK4 could regulate p38 activity in vivo. The Drosophila homolog, DMKK4, has been shown to target JNK but not p38 (Han et al., 1998) , whereas in Mkk4À/À murine ES cells there was no defect in p38 activation in response to a number of stresses (Yang et al., 1997b; Ganiatsas et al., 1998) . Meanwhile, experiments using Mkk4À/À MEFs have provided conflicting evidence as to whether there is a defect in p38 activation in response to TNFa and IL-1 Tournier et al., 2001; Brancho et al., 2003) . A role for MKK4 in UV radiation-induced activation of p38 in MEFs lacking both p38-specific MKKs, MKK3 and MKK6, has been demonstrated (Brancho et al., 2003) . In these cells some UV-induced p38 activity remains and this can be suppressed by reducing the level of MKK4 by small interfering RNA (siRNA) (Brancho et al., 2003) . Unlike the preferential Tyr phosphorylation of JNK by mammalian MKK4, p38 is phosphorylated equally well by MKK4 on both the activating Tyr and Thr residues (Brancho et al., 2003) .
Mechanism of MKK4 activation
MKKKs activate MKK4 by phosphorylating the Ser/ Thr residues in the Ser-Ile-Ala-Lys-Thr motif located in the T-loop of the kinase domain (KD) between subdomains VII and VIII (Cuenda, 2000; Kyriakis and Avruch, 2001) . Many MKKKs are capable of phosphorylating and activating MKK4 including members of the mitogen and extracellular-regulated kinase kinase (MEKK) and mixed-lineage kinase (MLK) families, as well as apoptosis signal-regulated kinase-1 (ASK1), transforming growth factor-b (TGFb)-activated kinase-1 (TAK1) and Tpl2 (Cuenda, 2000; Kyriakis and Avruch, 2001) (Figure 1a) . Different MKKKs have different specificities for the MKKs. For example, MEKK1 and TAK1 phosphorylate both MKK4 and MKK7, whereas MEKK4 appears to preferentially activate MKK4 (Kyriakis and Avruch, 2001; Takekawa et al., 2005) . This is consistent with the ability of MEKK1 to bind to the C-terminal DVD sites on both MKK4 and MKK7, whereas MEKK4 specifically interacts with MKK4 (Takekawa et al., 2005) . In addition to colocalizing the MKKKs with MKK4, these interactions may alter the conformation of MKK4 to enhance the accessibility of the Ser/Thr residues within the T-loop (Takekawa et al., 2005) . A model of signal transmission via MEKK1, MKK4 and JNK has been put forward whereby there are sequential bipartite interactions between MEKK1 and MKK4, and MKK4 and JNK (Xia et al., 1998) . It is proposed that MEKK1 binds to MKK4 and phosphorylates it resulting in the dissociation of the activated MKK4 from MEKK1, thereby allowing it to interact with and phosphorylate JNK (Xia et al., 1998) .
In addition to direct interactions between the protein kinase components of MAP kinase signaling cascades, these pathways can be regulated by their association with scaffold proteins that can act to colocalize the components of the cascade and facilitate their activation (Morrison and Davis, 2003) . A number of scaffold proteins interact with MKK4 and promote JNK activation including JNK-interacting protein-3 (JIP3) and JIP4 isoforms, plenty of SH3s (POSH), and barrestin-2 (McDonald et al., 2000; Xu et al., 2003b; Whitmarsh, 2006) . JIP3 and POSH play important roles in brain development, neuronal trafficking and apoptosis Xu et al., 2003a, b; Ha et al., 2005; Kim et al., 2005) , although how these functions relate to their MKK4-JNK scaffolding role is not fully understood. Similarly, the physiological role of the barrestin-2 complex with the JNK pathway is unclear (McDonald et al., 2000) . MKK4 is therefore a component of multiple signaling complexes, some of which are cell type dependent, and these may participate in distinct cellular processes.
Roles of MKK4 in vivo
Mice with a targeted deletion of the Mkk4 gene die during embryogenesis providing clear evidence that MKK4 has distinct functions in cells that cannot be complemented by other MKKs (Yang et al., 1997b; Ganiatsas et al., 1998) . The Mkk4À/À embryos die between E11.5 and E13.5 and display anemia and severe hemorrhaging in the liver Nishina et al., 1999) . They also display impaired liver formation and abnormal hepatogenesis, which correlates with significant apoptosis of liver cells Nishina et al., 1999) .
Further transgenic studies in mice have uncovered potentially important roles for MKK4 in the immune system and in the heart. The precise role of MKK4 in the immune system is unclear as separate studies in Mkk4À/À mouse chimeras developed using recombination-activating gene (RAG)2 blastocyst complementation came to different conclusions. One group reported that Mkk4 ablation impaired the development of both B-and T-cell lineages and that the mice had a greatly reduced thymus size (Nishina et al., 1997a, b) . Specific defects included reduced numbers of CD4 þ /CD8 þ double-positive (DP) immature thymocytes, increased sensitivity to apoptosis triggered by CD95 or CD3 crosslinking of both the DP thymocytes and peripheral T cells, and no transition from pro-B to pre-B cells in the bone marrow (Nishina et al., 1997a, b) . In contrast, a second group found no evidence that MKK4 was required for the development of T and B lymphocytes or for protecting thymocytes from cell death (Swat et al., 1998) . Instead, the mice exhibited lymphadenopathy and polyclonal B-and T-cell expansions suggesting an important role for MKK4 in maintaining peripheral lymphoid homeostasis (Swat et al., 1998) . The discrepancies between the studies could be owing to differences in the abilities of the homozygous Mkk4À/À ES clones being used to reconstitute B-and T-cell lineages in the context of RAG2-deficient blastocyst complementation. The generation of mice with specific inactivation of Mkk4 in T and B lymphocytes should help to resolve these issues.
The MKK4 signaling pathway may also contribute to cardiac hypertrophy, a process involving alterations in the morphology of cardiomyocytes and the extracellular matrix to compensate for systolic wall stress caused by an increased workload. If this occurs over a prolonged period it leads to wall thickening of the heart, chamber dilation and myocardial dysfunction. The expression of a dominant-negative mutant form of MKK4 in the rat heart leads to reduced JNK activity and a reduced hypertrophic response following pressure overload, implicating the MKK4-JNK pathway as a key pathway controlling cardiac hypertrophy (Choukroun et al., 1999) . However, the expression of dominant-negative mutants has the potential to affect multiple pathways; therefore, further investigations are required including the conditional deletion of the Mkk4 gene in mouse cardiomyocytes.
MKK4 in cancer
Over the past decade, a number of studies have supported a role for MKK4 in regulating steps in the development of cancers. Many studies propose that MKK4 is a tumor suppressor and a suppressor of metastasis, whereas other studies support a pro-oncogenic role for MKK4. This suggests a complex role for MKK4 and its downstream targets JNK and p38 in cancer development.
MKK4 mutations in cancer cells
The loss or inactivation of tumor suppressor genes promotes cancer formation and progression and can occur through loss of heterozygosity (LOH) or following homozygous gene deletion. The human MKK4 gene is located on chromosome 17p11.2 and lies centromeric to the p53 tumor suppressor gene (Yoshida et al., 1999) . This arm of chromosome 17 is one of the most frequently deleted in humans. A role for MKK4 as a tumor suppressor was first proposed by Teng et al. (1997) . Two tumor cell lines derived from pancreatic carcinoma and lung carcinoma were identified which harbored homozygous deletions that eliminated coding portions of the MKK4 locus (Teng et al., 1997) . In addition, 88 cancer cell lines that had been pre-screened for LOH were investigated and two nonsense mutations and three missense mutations were identified in cell lines derived from pancreas, breast, colon and testis (Teng et al., 1997) . Of these five intragenic mutations, four resulted in the inability of MKK4 to phosphorylate JNK in vitro indicating that they were loss of function mutations (Teng et al., 1997) . Indeed, the mutations result in either the premature termination of the protein product, thereby eliminating critical protein kinase subdomains, or amino-acid substitutions in functionally important residues that are conserved among the MKK family members (Teng et al., 1997) . A role for MKK4 as a tumor suppressor is supported by experiments demonstrating that a dominant-negative mutant of MKK4 promoted ES cell transformation and enhanced the tumorigenicity of ES cells injected into athymic nude mice (Cazillis et al., 2004) .
Since the original report investigating MKK4 mutations in cancer cell lines (Teng et al., 1997) , a number of studies have reported loss-of-function mutations in MKK4 at a fairly consistent rate (B5%) across a wide spectrum of primary cancers including those of the pancreas, bile duct, breast, prostate and ovary (Su et al., , 2002 Kim et al., 2001; Xin et al., 2004; Nakayama et al., 2006) . Missense and nonsense mutations in the MKK4 gene have also been identified in lung tumors in large-scale tumor screens (COSMIC: http://www. sanger.ac.uk/genetics/CGP/cosmic/). In pancreatic cancers there was a correlation between the loss of MKK4 protein and shorter survival times, with the MKK4-positive carcinomas carrying half the risk of death compared to MKK4-negative carcinomas (Xin et al., 2004) . It is likely that MKK4 may participate in a distinct tumor suppressive signaling pathway owing to the presence of coexistent mutations in other tumor suppressors including p53, BRCA2, DPC4 and p16 INK4a .
MKK4 as a metastasis suppressor
While loss of function of MKK4 may play a role in the formation of some primary tumors, it may also be linked with more advanced stages of cancer progression. The impaired expression of MKK4 in prostate and ovarian tumors appears to promote their metastasis (Yoshida et al., 1999; Yamada et al., 2002) , while reduced MKK4 mRNA levels have been reported in breast cancer to brain metastases (Stark et al., 2005) . In normal prostate tissue there are high levels of MKK4 protein expression in the epithelial compartment but not in the stromal compartment, whereas in neoplastic prostate tissues the levels of MKK4 were reduced and there was in inverse relationship between the reduction of MKK4 expression and its metastatic potential (Kim et al., 2001) . Experiments using the highly metastatic rat prostate cancer cell line AT6.1 (which lacks MKK4 expression) as a model system have demonstrated that the overexpression of MKK4 significantly reduces their metastatic ability (Yoshida et al., 1999) . Severe combined immunodeficient (SCID) mice were injected with either the parental AT6.1 cells, AT6.1 cells overexpressing MKK4 (AT6.1-Mkk4) or cells overexpressing a kinase-inactive mutant of MKK4 (AT6.1-Mkk4(KR)) and examined for lung metastases. The AT6.1-Mkk4 mice displayed fewer macroscopic lung metastases and survived longer than the mice injected with the parental line or the AT6.1-Mkk4(KR) cells, indicating that the kinase activity of MKK4 is essential for its metastasis suppression function (Yoshida et al., 1999; Vander Griend et al., 2005) (Figure 2) . Micrometastatic foci were detected in the lungs of AT6.1-Mkk4 mice suggesting that cells that have escaped from the primary tumor are growth inhibited in the lung (Yoshida et al., 1999) . A specific role for MKK4 in metastasis suppression is further supported by the fact that the growth rate of the primary tumor was not affected (Yoshida et al., 1999) .
Further complementation experiments demonstrated that the ectopic expression of the second JNK activator MKK7, but not of the p38 activator MKK6, could suppress metastasis by inhibiting the ability of AT6.1 cells to colonize the lung (Vander Griend et al., 2005) (Figure 2 ). This suggests that the JNK pathway, rather than the p38 pathway, is mediating the metastasis suppression by MKK4. Currently no mutations in the MKK7 gene in human tumors have been reported. MKK4 protein expression is also reduced in ovarian metastatic tissues compared to normal ovarian epithelial cells (Yamada et al., 2002) . To demonstrate a potential role for MKK4 in metastasis suppression in ovarian cancer, a similar complementation approach was used as that described above for examining prostate cancer metastasis. MKK4 was ectopically expressed in the human ovarian cell line SKOV3ip.1, which lacks endogenous MKK4 expression, and injected into SCID mice. This led to a significant decrease in overt metastatic implants on a number of tissues and organs compared to parental cells and increased the life span of the mice by 70% (Yamada et al., 2002) . In contrast to the prostate metastasis model discussed above, the ectopic expression of the p38 activator MKK6 also suppressed metastasis whereas expression of MKK7 did not, suggesting that p38, rather than JNK, may be the relevant MKK4 target in ovarian cancer (Hickson et al., 2006;  Figure 2 ).
Taken together, these studies suggest that MKK4 functions as a metastasis suppressor and may utilize distinct MAP kinases depending on the environmental context. It is likely that in different tissues and organs there may be distinct stimuli that dictate which MAP kinase pathway is targeted by MKK4.
Pro-oncogenic role of MKK4
Although there is an increasing body of evidence to support a role for MKK4 in tumor or metastasis suppression, there are also studies pointing to a prooncogenic role for MKK4. It is reported that in breast and pancreatic cancer cell lines that lack endogenous MKK4, the ectopic expression of MKK4 stimulates cell proliferation and invasion (Wang et al., 2004) . Conversely, the knock down of MKK4 expression by siRNA in the MKK4-positive breast cancer cell line MDA-MB-231 results in decreased anchorage-independent growth, increased susceptibility to apoptosis upon serum starvation and suppressed tumor growth in a mouse xenograft model (Wang et al., 2004) . Additional evidence for a role of MKK4 in cell proliferation comes from the demonstration that the expression of a dominantnegative mutant of MKK4 in H1299 non-small-cell lung cancer (NSCLC) cells cooperated with the inhibition of the phosphatidylinositol 3-kinase signaling pathway to block cell proliferation and reduce the size of H1299 NSCLC xenograft tumors , whereas the overexpression of a constitutively active mutant of MKK4 in human bronchial epithelial cell lines increased their proliferation and invasive properties (Khatlani et al., 2006) .
A recent study using a pancreatic cancer cell line PL5 (Panc 4.03) featuring the targeted disruption of the MKK4 gene has provided further support for a prooncogenic function of MKK4 (Cunningham et al., 2006) . Intravenous injection of the parental cells or MKK4 þ /À cells into mice led to numerous lung metastases, whereas the mice injected with the MKK4À/À cells had very few lung metastases (Cunningham et al., 2006) . When the mice were injected subcutaneously with MKK4À/À cells, the resulting tumors had a longer tumor volume doubling rate compared to mice injected with the parental or MKK4 þ /À cells, suggesting that MKK4 promotes tumor growth (Cunningham et al., 2006) . JNK activation, but not p38 activation, was compromised in the MKK4À/À cells indicating that MKK4 may be primarily acting through JNK to promote tumor growth (Cunningham et al., 2006) .
Taken together, these studies suggest that the role of MKK4 in regulating cancer development is highly context dependent and can vary according to tissue type, the environmental conditions and by interactions with other intracellular signaling pathways. 
Downstream targets of MKK4 in cancer
The protein kinase activity of MKK4 is required for its various reported roles in cancers. The major phosphorylation targets of MKK4 are the MAP kinases JNK and p38, suggesting they are likely to be required for mediating the effects of alterations in MKK4 expression or activity. Not surprisingly, considering the complexity of MKK4 involvement in cancer, there appears to be parallel complexities in the role of JNK in cellular transformation and tumor development . The role of p38 in cancer has received less attention, but there is an increasing body of evidence suggesting that it participates in tumor suppression (Bulavin and Fornace Jr, 2004) . In this section, we discuss how these MAP kinase pathways may regulate cancer development downstream of MKK4.
Role of JNK in cancer
Over the past decade many studies have implicated JNK in promoting cellular transformation by oncogenes including Ras, c-fos, Met and BCR-Abl, as well as epidermal growth factor (Smeal et al., 1991; Rodrigues et al., 1997; Bost et al., 1999; Behrens et al., 2000; Xiao and Lang, 2000; Hess et al., 2002) . Ras is activated by mutation in approximately 30% of human cancers and cooperates with the oncogene c-Jun, encoding a transcription factor target of JNK, to enhance cellular transformation (Schutte et al., 1989; Johnson et al., 1996) . Indeed, Ras is unable to transform c-Jun null fibroblasts (Johnson et al., 1996) . The role of JNK phosphorylation of c-Jun in cellular transformation is less clear. Ras induces the phosphorylation of the JNK sites in c-Jun and these sites have been demonstrated to be required for efficient co-transformation activity with Ras (Smeal et al., 1991; Derijard et al., 1994) . Moreover, the tumor suppressor p16 INK4a is proposed to interfere with Ras-c-Jun induced cell transformation by binding to JNK and inhibiting its phosphorylation of c-Jun (Choi et al., 2005) , while fibroblasts harboring c-Jun mutated at the JNK phosphorylation sites are resistant to Ras-induced transformation (Behrens et al., 2000) . However, the interpretation of the latter result is complicated by evidence that the transformation-resistant phenotype caused by the removal of the JNK sites can be reversed by mutating the C-terminal negative regulatory phosphorylation site of c-Jun that is targeted by glycogen synthase kinase-3 (Bost et al., 2001 ). In addition, in some cell types ERK MAP kinase, rather than JNK, may mediate Ras-induced c-Jun phosphorylation (Pulverer et al., 1991; Leppa et al., 1998) . Furthermore, studies using JNK-null fibroblasts demonstrated only a modest decrease in growth on soft agar compared to wild-type cells in response to oncogenic Ras, suggesting a minor contribution of JNK to Rasinduced transformation in these cells . Taken together these studies indicate a contextdependent role for JNK in cellular transformation.
JNK is also proposed to play a role in tumor development and high levels of JNK activity are reported in several cancer cell lines . In a Drosophila model of tumor formation, Ras and JNK have been demonstrated to be cooperative (Uhlirova et al., 2005) , whereas in mice carrying c-Jun with mutated JNK phosphorylation sites, c-Fos-induced osteosarcomas and skin tumors in response to constitutive Ras activation are reduced (Behrens et al., 2000) . A further example has been demonstrated in the Apc(Min) mouse model of intestinal cancer where the loss of c-Jun N-terminal phosphorylation leads to reduced tumor number and increased lifespan (Nateri et al., 2005) . The proposed mechanism involves phosphorylated c-Jun forming transcriptionally active complexes with TCF4 and bcatenin (Nateri et al., 2005) . Interestingly in liver, JNK promotes chemically induced hepatocarcinogenesis independently of c-Jun phosphorylation, suggesting other important targets exist (Eferl et al., 2003; Sakurai et al., 2006) .
Nuclear hormone receptors may also represent important targets of the JNK pathway in controlling cancer development. There is evidence that retinoid receptors can suppress tumorigenesis and that the loss of specific receptors promotes carcinogenesis in many tissues (Altucci and Gronemeyer, 2001) . Retinoid acid receptor a and retinoid X receptor a (RXRa) are phosphorylated by JNK leading to inhibition of retinoic acid (RA)-mediated transcriptional events (Adam-Stitah et al., 1999; Lee et al., 2000; Mann et al., 2005; Srinivas et al., 2005) . Surprisingly, RXRa is also directly phosphorylated by MKK4 on Tyr residues leading to the suppression of RA-mediated transcription (Lee et al., 2000) . Currently, RXRa represents the only MKK4 substrate identified apart from the JNK and p38 MAP kinases. These data suggest that the MKK4-JNK pathway antagonizes the tumor suppression function of RA signaling and may therefore promote tumorigenesis.
While the studies described above support a role for the JNK pathway in tumorigenesis, there is also an increasing body of evidence that JNK suppresses tumor development. The intravenous injection into athymic mice of Ras transformed wild type and JNK-null cells led to the formation of tumors in both sets of mice but a greatly increased tumor burden in the mice injected with JNK-null cells . These mice displayed an increased number of tumor nodules and increased tumor size. This study supports a model whereby JNK suppresses tumor formation induced by oncogenic Ras . A probable mechanism by which MKK4 and JNK act as tumor suppressors is through apoptosis. Indeed, in the Rasinduced JNK-null tumors very few apoptotic cells were detected compared to the wild-type tumors . The JNK pathway is a well characterized mediator of apoptosis (Davis, 2000) . In fibroblasts it is required for stress-induced cytochrome c release from mitochondria, a key driver of apoptosis (Tournier et al., 2000) . Further work to elucidate the mechanisms involved has demonstrated a JNK-dependent requirement for the proapoptotic Bcl2 family members Bax and Bak in cytochrome c release (Lei et al., 2002) . The regulation of Bax and Bak may occur by JNK phosphorylation of two additional Bcl2 family proteins, Bim and Bmf (Lei and Davis, 2003; Putcha et al., 2003; Figure 3a) . This leads to their release from sequestration in dynein and myosin V complexes and the promotion of Bax and Bak activation by an unknown mechanism (Lei and Davis, 2003) . Recently, it was reported that Bax itself may be a direct target of JNK and p38 signaling pathways and that these pathways promote Bax translocation to the mitochondria before apoptosis (Kim et al., 2006) . JNK may also contribute to Bax translocation to the mitochondria through the phosphorylation of members of the 14-3-3 family. Bax is normally sequestered in the cytoplasm by binding to 14-3-3 but upon stress JNK phosphorylates 14-3-3 leading to the dissociation of Bax and its translocation to the mitochondria (Tsuruta et al., 2004) . In addition to the phosphorylation of proapoptotic Bcl2 family members, JNK phosphorylates and inactivates the anti-apoptotic Bcl2 family proteins Bcl2, Bcl-XL and Mcl-1, thus further contributing to Bax activation and apoptosis (Maundrell et al., 1997; Yamamoto et al., 1999; Fan et al., 2000; Deng et al., 2001; Inoshita et al., 2002 ; Figure 3a) .
Recently, it has been proposed that JNK may act as a tumor suppressor by regulating the autocrine expression of TGF-b1 (Ventura et al, 2004; Figure 3a) . Increased expression levels of TGF-b1 have previously been reported to contribute to cancer progression and the inhibition of TGF-b1 signaling blocks tumor growth in mice injected with Ras transformed cells (Ventura et al, 2004; Bierie and Moses, 2006) . JNK-null fibroblasts display increased TGF-b1 levels compared with wildtype cells and this correlates with increased invasive behavior and proliferation (Ventura et al, 2004) . This effect was attributable to a distal promoter region in the TGF-1b gene that binds to c-Jun and represses transcription by recruiting the histone deacetylase HDAC3 in wild-type cells, but has reduced binding to c-Jun and HDAC3 in JNK-null cells. This suggests that JNK phosphorylation of c-Jun is required for c-Jun/ AP-1 recruitment to the TGF-1b promoter. Conversely, SMAD3/SMAD4 recruitment to the promoter is enhanced in the JNK-null cells and may contribute to the auto-induction of TGF-1b gene expression (Ventura et al., 2004) . However, multiple levels of crosstalk exist between the TGF-b and JNK signaling pathways. For example, JNK can also positively contribute to TGF-binduced gene expression via regulation of AP-1 activity and JNK can target SMAD2 and SMAD3 for phosphorylation leading to the upregulation of TGFb-responsive genes .
The different isoforms of JNK may have distinct roles in tumorigenesis. Although the ubiquitously expressed JNK1 and JNK2 display significant functional redundancy in many cellular processes, there is evidence that they have distinct roles in skin tumor development. JNK1-null mice display enhanced skin tumor development in response to phorbol ester whereas there is suppression of skin tumorigenesis in JNK2-null mice (Chen et al., 2001; She et al., 2002) . This suggests that in this model JNK1 has a tumor suppressor role and that JNK2 promotes tumorigenesis. Further support for a specific role of JNK1 in tumor suppression comes from the demonstration that it is required for tumor surveillance by the immune system (Gao et al., 2005) , whereas a preferential role for JNK2 in tumorigenesis is supported by studies in glioblastoma, prostate, and lung carcinoma cell lines (Bost et al., 1999; Potapova et al., 2000; Yang et al., 2003; Cui et al., 2006) . The molecular mechanism underlying these opposing actions of JNK1 and JNK2 are unclear as unique substrates for individual JNK isoforms have not been uncovered. It has been proposed, based on experiments using JNK1-or JNK2-deficient fibroblasts, that JNK1 and JNK2 differentially regulate c-Jun stability and transcriptional activity depending upon their activation state (Sabapathy et al., 2004) . However, an alternative explanation negatively regulates cyclin D1 both by reducing gene transcription and by promoting protein instability and thereby blocking the G1/ S transition. The p38 pathway, via MAPKAPK2, also downregulates the activity of CDC25 family members thereby inhibiting cell cycle progression. The tumor suppressor p53 is a direct target of p38 phosphorylation, which promotes its stability and transcriptional activation leading to cell cycle arrest and apoptosis.
is based on the observation that JNK1 activity increases in the absence of JNK2 protein, but not upon inhibition of JNK2 activity (Jaeschke et al., 2006) . Using a chemical genetic approach it was demonstrated that JNK1 and JNK2 are both positive regulators of c-Jun, rather than being antagonistic (Jaeschke et al., 2006) . It is possible, therefore, that the increased tumor suppression observed in JNK2-null mice could be owing to increased JNK1 activity, rather than owing to the loss of JNK2.
The third JNK isoform, JNK3, is mainly expressed in brain and testis and has functions distinct from JNK1 and JNK2 (Yang et al., 1997a) . One study has reported that 10 out of 19 human brain tumors that were examined contained mutations in the JNK3 gene . Although this suggests that JNK3, like MKK4, may also be a tumor suppressor gene, further studies are required to demonstrate a direct effect of JNK3 loss on brain tumor development.
Role of p38 in cancer
The role of members of the p38 family in cancer is less well established, but there is increasing evidence that p38 may act as a tumor suppressor (Bulavin and Fornace Jr, 2004) . For example, MEFs lacking the p38 activators MKK3 and MKK6 display defects in serum starvationinduced growth arrest and the subcutaneous injection of SV40-large-T-antigen immortalized Mkk3À/ÀMkk6À/À fibroblasts into athymic mice results in a significantly increased tumor burden compared to the injection of wild-type cells (Brancho et al., 2003) . p38 has been demonstrated to negatively regulate cell cycle progression and proliferation through several mechanisms. Targets of p38 signaling include cyclin D1, CDC25 and p53 (Bulavin and Fornace Jr, 2004; Figure 3b) . Cyclin D1 collaborates with cyclin-dependent kinase 4 (CDK4) to regulate the G1/S cell cycle transition and the loss of regulation of cyclin D1 expression levels can contribute to tumor formation (Ortega et al., 2002) . Cyclin D1 levels can be regulated by p38 both at the level of gene transcription and post-translationally (Lavoie et al., 1996; Casanovas et al., 2000; Brancho et al., 2003) . p38 negatively regulates the Cyclin D1 promoter (Lavoie et al., 1996; Brancho et al., 2003) , potentially via phosphorylation and stabilization of the HBP1 repressor protein (Xiu et al., 2003) , whereas the cyclin D1 protein is phosphorylated at Thr286 by p38 under certain stress conditions and this leads to its proteasome-dependent degradation (Casanovas et al., 2000) . The expression of a cyclin D1 mutant that cannot be phosphorylated at Thr286 promotes cellular transformation of fibroblasts and tumor growth in mice (Alt et al., 2000) . p38 also indirectly affects cyclin D1/CDK4 activity through upregulating the expression of the cyclin-dependent kinase inhibitors p16
Ink4a and p19 Arf . p38 regulation of these cyclin-dependent kinase inhibitors is controlled by p53-induced phosphatase-1 (Wip1), although the precise mechanism is unclear . It is reported that there is decreased p38 activity in human cancers where Wip1 is overexpressed (Bulavin et al., 2002) , whereas in Wip1-null mice, p38 activity and p16
INK4a levels are increased and the mice are protected from the early onset of mammary tumors in response to Ras, Neu and ErbB2 oncogenes Demidov et al., 2006) . The addition of a pharmacological inhibitor of p38 activity to the Wip1-null mice reduced p16
INK4a expression and led to the formation of mammary tumors , whereas mice bearing a constitutively active form of the p38 activator MKK6 suppressed the tumor-prone phenotype of mice overexpressing Wip1 in mammary epithelium (Demidov et al., 2006) .
The members of the CDC25 protein phosphatase family are also targets of p38. CDC25A is overexpressed in over 40% of primary human breast cancers and activates CDK2 by removing inhibitory phosphorylation sites (Bartek and Lukas, 2001) . Osmotic stress leads to the phosphorylation of CDC25A on Ser75 resulting in its degradation and thereby suppressing CDC25A activity and potentially promoting tumor suppression (Goloudina et al., 2003) . This effect is mediated by the p38 pathway, although it is unclear which protein kinase is responsible for directly phosphorylating this site in CDC25A (Goloudina et al., 2003) . The p38 pathway can also negatively regulate the G2/M cell cycle transition by phosphorylating the other members of this protein phosphatase family. CDC25B is phosphorylated at Ser309 and CDC25C at Ser216, which triggers their binding and sequestration by 14-3-3 proteins and thereby prevents activation of the Cdc2, an important kinase that drives the G2/M transition (Bulavin et al., 2001) . Initially, it was proposed that p38 might directly phosphorylate CDC25B and CDC25C (Bulavin et al., 2001) , but recent studies supported by genetic studies in yeast, indicate that MAPK-activated protein kinase-2 (MAPKAPK2), a kinase downstream of p38, is responsible for the phosphorylations in vivo (Lopez-Aviles et al., 2005; Manke et al., 2005) (Figure 3b ). These studies suggest that p38 can block cell cycle progression via interactions with distinct members of the CDC25 family and thereby contribute to tumor suppression.
The tumor suppressor p53 plays a central role in many cellular events including regulating cell cycle checkpoints, apoptosis and genomic stability (Vogelstein et al., 2000) . In response to stress, particularly genotoxic stress, p53 is stabilized by dissociation from ubiquitin ligases, such as murine double minute 2 (MDM2), and by Ser/ Thr phosphorylation at multiple sites which also contribute to its transcriptional activity (Vogelstein et al., 2000) . The activation of the p38 pathway leads to enhanced p53 transcriptional activity, which can lead to cell cycle arrest and apoptosis (Bulavin et al., 1999; Takekawa et al., 2000; Figure 3b ). p38 phosphorylates human p53 at Ser33 and Ser46 in response to several stresses and may indirectly lead to p53 phosphorylation at Ser392 via the activation of casein kinase-2 (Bulavin et al., 1999; Bulavin and Fornace Jr, 2004) . The phosphorylation of Ser33 and Ser46 of p53 is required for the recruitment of the prolyl isomerase Pin1 which contributes to p53 stability and function (Zacchi et al., 2002; Zheng et al., 2002) . Interestingly, JNK can also phosphorylate p53 and regulate its stability but it remains unclear how JNK contributes to specific p53 functions (Buschmann et al., 2001) .
Similar to the case of p53, both p38 and JNK can phosphorylate the androgen receptor (AR) at Ser650 and promote its nuclear export in prostate cancer cells thereby reducing AR-mediated transcription (Gioeli et al., 2006) . It was also demonstrated that decreasing MKK4 or MKK6 expression levels by siRNA led to increased AR nuclear accumulation and transactivation. (Gioeli et al., 2006) . As the AR plays a key role in the progression of prostate cancer, then loss of function mutants of MKK4 may hypersensitize the AR to androgen and promote the androgen-independent diseased state.
The studies discussed here indicate a potential tumor suppressor role for p38. However, there is also limited evidence that p38 contributes to lung metastasis of tumor cells. A recent study using mice heterozygous for the p38a isoform found that these mice had markedly fewer colonies of tumor cells in lungs in an in vivo metastasis assay (Matsuo et al., 2006) . Therefore p38, like JNK, may play important roles in both tumor suppression and oncogenesis downstream of MKK4.
Concluding remarks
The signaling pathways featuring MKK4, JNK and p38 have been studied intensely at the molecular level, and recent genetic studies in mice have provided important information on their in vivo functions. There is increasing evidence to support an important role for MKK4 pathways in controlling cancer development in humans. A function for MKK4 as a tumor suppressor is supported by the fact that the MKK4 gene is mutated at a frequency of 5% in a number of cancer types and that complementation experiments support a role in the suppression of metastasis from prostate and ovary. In contrast, studies in other cell types suggest that MKK4 and JNK participate in tumor promotion. To more directly address the role of MKK4 in tumor suppression or promotion, appropriate mouse models featuring tissue-specific Mkk4 deletion or mutations of the Mkk4 gene will need to be generated and characterized. These studies will need to be correlated with similar studies to address which branches of the MKK4 pathway are relevant in particular cancer types. A full understanding of the role of MKK4 and its downstream targets will be required for designing strategies for tumor therapy using small molecule inhibitors of MKK4 or the JNK and p38 MAP kinases.
